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Abstract: 
 
Jarid1c is a master regulator of transcription and represses expression of specific target genes. 
Mutations in the Jarid1c gene have been found to cause mental retardation, epilepsy, aggression, 
and autism, indicating that this gene plays an important role in brain development and function. 
It is not clear as to exactly how Jarid1c causes behavioral defects and it is thought that Jarid1c 
perhaps plays a role in neuronal differentiation in the embryonic brain. Jarid1c was silenced in 
embryonic carcinoma P19 cells using Lentiviral particles containing Jarid1c-shRNA constructs. 
Neuronal differentiation was then induced in these Jarid1c knockdown P19 cells as well as in 
control P19 cells, which were treated with non-targeting shRNAs. The effects of silencing the 
Jarid1c gene was assessed with SuperArray PCR panels analyzing 84 neurotrophin genes. Fus 
and Gfra3 were found to be up-regulated in the Jarid1c knockdown relative to control P19 cells 
on Day 0 before neuronal induction had begun. On Day 4, Ntrk1 was up-regulated while Il1r1 
and Il6 were down-regulated in the Jarid1c knockdown cells. By Day 10, when P19 cells were 
fully differentiated, no detectable difference was found in the 84 genes’ expression in the Jarid1c 
knockdown and control P19 cells. These results indicate that Jarid1c is involved in neuronal 
differentiation as well as in gene expression in pluripotent stem cells. 
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Introduction and Background: 
 
This project studies the Jarid1c gene and its role in gene expression and neuronal differentiation. 
Jarid1c (Jumonji AT-rich interactive domain 1C), formally called ‘SMCX,’ is involved in 
transcriptional regulation and chromatin remodeling. Mutations in this gene can cause X-linked 
mental retardation (XLMR) in humans. XLMR is a heterogeneous disease and can involve 
genetic, stochastic, and/or environmental factors. The disease affects 2 out of 1000 males causing 
symptoms of mild to severe mental retardation (Ropers and Hamel, 2005).  
In a study by Jensen et al. (2005), mutations in Jarid1c were found in several patients with 
XLMR, including frameshift mutations, nonsense mutations, and missense mutations. Frameshift 
mutations can lead to a premature stop codon. The mutations cosegregate with the phenotype. A 
northern blot hybridization of RNA on affected patients resulted in an almost undetectable 
Jarid1c transcript. This led the authors to conclude that the phenotype in these patients was due 
to a loss of the Jarid1c protein, likely due to the nonsense-mediated mRNA decay (NMD) 
mechanism (Holbrook et al., 2004). The Jarid1c RNA levels in patients with missense mutations 
were not notably different, due to extreme shortening of the protein or an abnormal protein 
(Jensen et al., 2005).  
Missense changes in Jarid1c in different patients have been found in the conserved C5HC2 zinc-
finger domain as well as outside of this area. Mutations outside of this domain involved changes 
such as the introduction of a proline which adds a kink to the backbone of a protein, or changing 
a glutamic acid to a lysine which changes the charge of a protein. The seven Jarid1c mutations 
found by Jensen et al. (2005) are thought to affect protein function and to be responsible for 
cognitive defects found in patients with XLMR. These mutations are found at a frequency of 
7 
 
2.8%, making Jarid1c one of the most prevalently mutated genes found in XLMR (Tzschach et 
al., 2006). They can cause sydromic and non-syndromic XLMR.  
Jarid1c is a member of a subfamily of four proteins, Jarid1d (SMCY), Jarid1a (RBP2), and 
Jarid1b (PLU-1) (Klose et al., 2006), each with their own influence over biological processes and 
diseases. Jarid1d has been identified as a male-specific antigen. Jarid1a has been found to be a 
pRB binding protein and has a role monitoring cellular response when DNA has been damaged 
(Ahmed et al., 2004).  Jarid1b is expressed in the ovary, testis, and transiently in mammary 
glands while pregnant and has been shown to be up-regulated in breast and testis cancer (Lu et 
al., 1999).  
Jarid1c and Jarid1d are known to make up an X-Y homologous gene pair from the original 
mammalian sex chromosomes (Delbridge et al., 2004). This suggests the possibility that Jarid1c 
and Jarid1d are functionally equivalent. These two are expressed in sex-specific manners, with 
Jarid1c being expressed in a higher level in females during adulthood. The expression of Jarid1d 
cannot compensate for the female bias in X-gene expression (Xu et al., 2002). This led Jensen et 
al. (2005), to believe that they are not functionally equivalent after all, and that Jarid1c is 
essential for normal brain function.  
Jarid1c as a Histone Demethylase 
Jarid1c is also known to be a histone demethylase, meaning it regulates chromatin structure as 
well as gene transcription (Iwase et al., 2007). Five lysine residues on the histone tails of 
histones H3 and H4 as well as K79 within H3’s core have been identified as methylation sites 
(Margueron et al., 2005). DNA-damage response as well as transcriptional activation and 
repression are affected by histone methylation (Sanders et al., 2004). Lysine methylation can be 
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done in three different ways: mono-, di-, and trimethylation. It has been found that histone H3 
lysine 4 (H3K4) trimethylation regulates transcription in a positive manner by recruiting 
complexes that cause chromatin remodeling (Liang et al., 2004; Santos-Rosa et al, 2003).  
In a study done by Iwase et al. (2007), it was shown that Jarid1c is a H3K4 trimethyl-
demethylase and catalyzes the methylation of H3K4me3 to H3K4me1. When Jarid1c is 
overexpressed in cultured cells, there is a reduction of H3K4me3. A reduction was also found 
with the three other family members, Jarid1d, Jarid1a, and Jarid1b. One of the PHD fingers of 
Jarid1c bound to H3K9me3, which caused Iwase et al. to suggest that cross talk occurs with 
H3K4 and H3K9 methylation in repressing transcription. When there are mutations in Jarid1c, 
such as in XLMR, this compromises the demethylase activity and H3K9me3 binding ability 
(Iwase et al., 2007), which may be a common cause of the disease. 
Iwase et al. (2007) used zebrafish as a model and inhibited Jarid1c. They found that there were 
defects in neuronal development as well as impaired dendritic morphogenesis in culture. An 
RNAi-resistant wild-type Jarid1c transgene was able to restore growth of dendrites after a 
Jarid1c knockdown. However, if the transgenes had point mutations, it caused the demethylation 
activity to be disrupted, and the dendrites’ growth was unable to be restored. This suggests a link 
between Jarid1c’s demethylase role and dendritic development.  
P19 Embryonic Carcinoma Cells 
Embryonal Carcinoma (EC) P19 cells can be used as a model system for neuronal 
differentiation. These cells are capable of differentiating into many types of neurons as well as 
glia (Bain et al., 1994). P19 stem cells can be cultured in the undifferentiated state and managed 
easily. They can be induced to differentiate all at once into neuron-like cells.  
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P19 cells were first isolated by Rogers and McBurney in 1982 (a) from a teratocarcinoma which 
was grafted onto C3H/He mice. The tumor that resulted was removed and dissociated so it could 
be grown in tissue culture. A clonal cell line was chosen and named P19 embryonal carcinoma 
cells. P19 cells and their clones are able to divide rapidly and can differentiate, even after many 
passages in culture (Bain et al., 1994). This allows both normal and mutated proteins to be 
overexpressed. They can also be blocked by anti-sense RNA.  
When P19 cells are cultured, they must be induced to differentiate by a chemical inducer after 
formation of aggregates. To induce differentiation of cardiac- and skeletal muscle-like cells, 
dimethylsufoxide can be used (McBurney, 1982b).  To induce neuron, fibroblast, and glia-like 
cell differentiation, retinoic acid (RA) can be used (Jones-Villeneuve et al., 1982).  
The affects of RA on cells is mediated by two major families of receptors, retinoic acid receptors 
(RARs) and retinoid X receptors (RXRs) (Bain et al., 1994). Each family has α, β, and γ 
receptors, which are produced by separate genes with various isoforms that result from 
alternative splicing (Leid et al., 1992). Before cells are differentiated, there are very low levels of 
RARs. Once RA is introduced, the amounts of RARα and RARβ mRNA increase greatly, while 
encoding RARγ is greatly repressed. The RAR family has been found to play a key role in P19 
neuronal differentiation (Bain et al., 1994). The RAR family members possess inducible trans-
acting factors and have been shown to be regulators of gene expression (Leid et. al, 1992).  
Neuron-like cells cultured from P19 cells are very similar to cultured brain cells (Bain et al., 
1994). These cells have small cell bodies with long projections that resemble axons and 
dendrites. They are stable post-mitotic cells, as are normal neurons. Neurotransmitters, 
associated gene transcripts, and enzymes have been found to be expressed in these neuron-like 
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cells, most being characteristic of cells in the central nervous system. Functional synapses have 
also been discovered (McBurney, M.W. et al., 1988). 
RNA Interference: Gene Silencing Methods 
Double-stranded RNA (dsRNA), for example, short-hairpin RNAs (shRNAs), can be utilized to 
silence target gene expression (Applied Biosystems, 2009). Gene silencing by dsRNAs has been 
termed RNA interference (Howard Hughes Medical Institute, 2005). RNAi occurs in many 
mammals including mice and humans. It is able to protect the genome from certain viruses as 
well as ‘jumping genes.’ It plays an important role in gene expression regulation by down-
regulating certain genes at specific times. RNAi can be triggered by dsRNAs which are 
homologous to portions of target genes.  
RNA interference begins when a long dsRNA molecule is present, which could have been 
introduced or the product of a virus or a jumping gene (HHMI, 2005). Viruses can be used to 
target a specific gene. In the case of Jarid1c, the Lentivirus is used. The Lentivirus is used for 
cells that do not divide or are hard to transfect such as blood or stem cells (System Biosciences, 
2009). The constructs integrate into the genomic DNA and do not require cell replication.  
The process of RNAi using the Lentivirus starts with a short-hairpin Plasmid DNA (System 
Biosciences, 2009). This plasmid enters the cell by lipid-based transfection. The shRNA is 
transcribed once inside the cell. The loop in the shRNA is removed by the RNase III-like 
enzyme, Dicer, and processed into small, 20-25 nucleotide long small interference RNAs 
(siRNAs). The siRNA then binds to several proteins which form an RNA-induced silencing 
complex (RISC). The siRNA are then separated utilizing energy from adenosine triphosphate 
(ATP), which causes the RISC to be activated. The siRNA/RISC complex associates with target 
11 
 
RNA and cleaves it. Other proteins further degrade the mRNA, which prevents them from 
producing proteins. This process can affectively and permanently silence any gene using 
Lentiviral transduction particles with shRNA constructs (See Figure 1).  
 
Figure 1: RNA Interference Process Using shRNA Plasmid DNA 
The XLMR gene, Jarid1c, causes many neurological disorders including mental retardation, 
epilepsy, aggression, and autism. It is unclear as to exactly how Jarid1c causes these behavioral 
defects. A possibility is that Jarid1c plays a role in neuronal differentiation in the embryonic 
brain. To model what occurs during embryonic development, embryonic carcinoma P19 cells 
(System Biosciences, 2009) 
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were used because they can be induced to differentiate into neurons. To explore Jarid1c’s role in 
neuronal differentiation, it was necessary to knockout or knockdown Jarid1c, which was done by 
Lentivirus and RNAi. The effect of this silencing of Jarid1c was assessed with SuperArray PCR 
panels on a real-time PCR machine.  
Materials and Methods:  
P19 Cell Culture: 
EC P19 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM). This medium 
contained 10% fetal bovine serum (FBS) and 1% P/S antibiotic. The cultures were grown in a 
37˚C incubator supplemented with 5% CO2. The cells were cultured in NUNC
TM
 adhesive Petri 
dishes from frozen stock kept in an -80˚C freezer. The medium was refreshed every other day.  
Lentiviral Transduction: 
The Lentiviral transduction (See Figure 3) was initiated on Day 1 by inoculating dispersed P19 
cells into a 12 well plate with 1mL DMEM. On Day 2, the medium was refreshed and Lentiviral 
particles containing Jarid1c shRNA constructs were added, while non-targeting shRNAs were 
added to form a negative line (Figure 2). 
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Figure 2: Lentiviral transduction 12-well plate. Row 1, no particles were added. Row 2, non-
targeting shRNAs were added to create a negative control cell line. Row 3, Lentiviral particles 
containing Jarid1c shRNA constructs were added.  
 
On Day 3, the viruses were removed by replacing the medium. On Day 4, DMEM containing 
puromycin was added to the wells to select for cells that had been successfully transduced with 
Lentivirus. On Day 5 and on, the medium was replaced every other day, until a culture of stable 
puromycin-resistant cells was established.  
.  
 
 
 
 
 
 
Figure 3: Timeline of Lentiviral transduction.  
No 
 
Negative 
 
Jarid1c 
0μL  2 μL  4 μL        8 μL 
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Neuronal Induction: 
Neuronal differentiation (Figure 4) was initiated by plating the Jarid1c Lentivirus and negative 
cell lines created in the Lentiviral induction in DMEM containing 0.3μM retinoic acid (RA). The 
cells were transferred to non-adhesive Falcon
TM
 Petri dishes, which persuades the cells to form 
aggregates by Day 4. On Day 4, the cells were dispersed using trypsin, a serine protease, and 
then replated to adhesive NUNC plates.  
On Day 5, DMEM containing cytosine arabinoside (Ara-C) was used to refresh the cells. Ara-C 
inhibits cell division, so only neuron-like cells will be selected. Neurons were differentiated by 
Day 6 and the medium was replaced every other day. On Day 10, cells were collected for gene 
analysis.  
 
Figure 4: Timeline of Neuronal differentiation.  
Expression of Neurotrophin Genes: 
RNA was extracted from samples collected at each of the three time points: D0, D4, and D10 
using the RNeasy kit by Qiagen. Any DNA left in the samples was removed using the DNA-free 
Kit by Applied Biosystems. cDNA synthesis was done using RT
2
 Real Strand Kit. The cDNA 
expression quantification was performed following SABiosciences instructions on an ABI 7500 
real-time PCR system. The relative expression of each gene was calculated using the following 
formula: 
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ExpressionGOI = 2
-Ct
 
Ct = CtGOI – CtAVG(HKG) 
CtGOI: Ct value of gene of interest; 
CtAVG(HKG): average Ct value of five housekeeping genes.  
Mouse neurotrophin plates were used for real-time PCR and were laid out as shown in Figure 5. 
 
 
 
 
 
 
 
Figure 5: Layout for Neurotrophin receptor real-time PCR plates 
Appendix I displays the detailed gene descriptions for the 84 genes above.  
Results: 
It was found by PCR analysis that Jarid1c expression was indeed diminished in P19 Jarid1c 
knockdown cells when compared with negative control cells that had been transfected with non-
targeting shRNAs. Expression of Jarid1d, a member of the Jarid1c family, was not affected, 
which argues against an off-target effect.  
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P19 Jarid1c knockdown cells were induced to differentiate into neuron-like cells. This is a clear 
indication that Jarid1c is not indispensable for neuronal induction to occur. Figure 6 shows the 
process of neuronal induction. It shows the P19 cells growing on NUNC plates on Day 0. On 
Day 4 the cells have formed aggregates in Falcon plates while being treated with retinoic acid. 
By Day 10 the cells had fully differentiated after being treated with Ara-C and replated on 
adhesive NUNC plates. The neuronal cell body and neurite can be clearly seen in the 
photograph.  
 
 
 
 
Figure 6: Process of Neuronal Differentiation 
   
Figure 7: Neurons, Day 10 
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In Figure 7, different views of neurons can be seen at 10x and 20x magnification. These photos 
show the complex connections between neuronal cell bodies that occur.  
Mouse neurotrophin receptor PCR panels were used to analyze the expression of 84 different 
neurotrophin signaling-related genes (See Figure 5) in Jarid1c knockdown and control cells at 
Day 0, Day 4, and Day 10.  Most genes were expressed at relatively the same rate between cell 
types. However, on Day 0, prior to initiation of neuronal differentiation, Fus and Gfra3 were 
found to be up-regulated in the Jarid1c knockdown when compared to the negative control cells. 
This was important to note as a baseline when comparing Day 4 and Day 10. 
On Day 4, the neurotrophin receptor gene, Ntrk1 (Neurotrophic tyrosine kinase receptor, type 1) 
was upregulated in Jarid1c knockdown cells. Il6 (Interleukin 6) and Il1r1 (Interleukin receptor 1, 
type1) were found to be down-regulated at Day 4 in Jarid1c knockdown cells. Figure 8 shows a 
quantification of the relative expression of each of the three genes.  
 
 
 
 
 
 
 
Figure 8: Relative Expression of 
three neurotrophin receptor genes 
in Jarid1c knockdown cells vs. 
negative control cells.  
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On Day 10, when P19 cells were fully differentiated there was no difference detected by PCR 
between the expression of the 84 genes in Jarid1c knockdown and negative control.  
 
Discussion: 
Jarid1c is a histone demethylase master regulator gene which suppresses transcription of certain 
target genes. Mutations in this gene can cause neurological disorders such as mental retardation, 
aggression, epilepsy, and autism. It is unclear as to how exactly Jarid1c causes these behavioral 
defects. One hypothesis was that Jarid1c plays a role in neuronal differentiation in the embryonic 
brain. This study used P19 embryonic carcinoma stem cells as an in vitro model, because they 
can easily be induced to differentiate into neurons. Lentiviral transduction particles were used to 
permanently silence Jarid1c expression using shRNA constructs. The affects of this silencing at 
three time points, Day 0, Day 4, and Day 10 were analyzed with SuperArray PCR panels on a 
real-time PCR machine.  
Jarid1c was stably silenced using the Lentivirus transduction method. These Jarid1c knockdown 
cells were able to fully differentiate into neurons, indicating that Jarid1c is not essential for 
neuronal differentiation.  
On Day 4 it was found that the expression of three genes was different between Jarid1c and 
negative control cell lines. Ntrk1 was found to be up-regulated in Jarid1c knockdown cells. This 
gene encodes for a neurotrophic tyrosine kinase receptor (Weizmann Institute of Science, 2009). 
It is capable of self phosphorylation. It is thought to lead to cell differentiation and play a role in 
specifying the subtype of neuron. The up-regulation of Ntrk1 may be compensating for the lack 
of Jarid1c in the Jarid1c knockdown cells and taking over some of its roles.  
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Il6 and Il1r1 were found to be down-regulated in the Jarid1c knockdown cells. Il6 is a cytokine 
with many different functions, such as playing a role in differentiating B-cells and inducing 
myeloma and plasmacytoma growth (Weizmann Institute of Science, 2009). It also induces nerve 
cell differentiation. A down regulation of this gene suggests that Jarid1c normally would induce 
this gene to help in neuronal differentiation. A mutation in Jarid1c may cause a similar down-
regulation in Il6, which could be tied to certain XLMR phenotypes.  
Il1r1 was also down-regulated. It belongs to a family of interleukin 1 receptors (Weizmann 
Institute of Science, 2009). It is a receptor for interleukin alpha, beta, and interleukin 1 receptor 
type 1. It is also a mediator in cytokine induced inflammatory responses. Il1r1 is a member of a 
cytokine receptor gene cluster on chromosome 2q12. A study conducted by Wainwright et al. 
(2005) suggests that genes on chromosome 2 may play an important role in human intelligence. 
A down-regulation in this receptor gene may also occur in Jarid1c mutations and could also be 
linked to XLMR phenotypes, such as lowered intelligence.  
In future studies of Jarid1c and neuronal differentiation, it would be interesting to see how 
mutated forms of Jarid1c, instead of simply knocking down Jarid1c, affect neuronal 
differentiation. It is possible that the same genes would be up- and down-regulated, but it is 
possible that additional genes may be affected. This study could also be linked with a mouse 
model so that the affects of the Jarid1c silencing could be seen. Behavioral studies could be 
conducted to see if lack of Jarid1c causes changes in behavior. Detailed studies could be done on 
the differences in neuron structure between the Jarid1c knockdown cells and negative control 
cells. This would shed more light on Jarid1c’s role in neuronal differentiation.  
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Appendix I: Mouse Neurotrophin and Receptor PCR plate Gene Descriptions 
Gene Table  
Position Unigene GeneBank Symbol Description Gene Name 
A01  Mm.44245 NM_007407 Adcyap1r1 Adenylate cyclase activating polypeptide 1 receptor 1 2900024I10Rik/AI846590 
A02  Mm.56897 NM_009711 Artn Artemin neublastin 
A03  Mm.19904 NM_007527 Bax Bcl2-associated X protein BAX 
A04  Mm.257460 NM_009741 Bcl2 B-cell leukemia/lymphoma 2 AW986256/Bcl-2 
A05  Mm.1442 NM_007540 Bdnf Brain derived neurotrophic factor BDNF 
A06  Mm.4880 NM_019626 Cbln1 Cerebellin 1 precursor protein AI323299 
A07  Mm.3521 NM_009827 Cckar Cholecystokinin A receptor AW106902 
A08  Mm.425178 NM_016673 Cntfr Ciliary neurotrophic factor receptor Cntfralpha 
A09  Mm.290689 NM_205769 Crh Corticotropin releasing hormone CRF/Gm1347 
A10  Mm.316614 NM_198408 Crhbp Corticotropin releasing hormone binding protein CRH-BP 
A11  Mm.1892 NM_007762 Crhr1 Corticotropin releasing hormone receptor 1 CRFR1/Crhr 
A12  Mm.236081 NM_009953 Crhr2 Corticotropin releasing hormone receptor 2 CRF-R2/CRFR2alpha 
B01  Mm.44065 NM_009987 Cx3cr1 Chemokine (C-X3-C) receptor 1 CX3CR1 
B02  Mm.1401 NM_009911 Cxcr4 Chemokine (C-X-C motif) receptor 4 CD184/Cmkar4 
B03  Mm.1626 NM_007987 Fas Fas (TNF receptor superfamily member 6) AI196731/APO-1 
B04  Mm.457975 NM_008006 Fgf2 Fibroblast growth factor 2 Fgf-2/Fgfb 
B05  Mm.8846 NM_013518 Fgf9 Fibroblast growth factor 9 FGF9 
B06  Mm.265716 NM_010206 Fgfr1 Fibroblast growth factor receptor 1 AW208770/FLG 
B07  Mm.246513 NM_010234 Fos FBJ osteosarcoma oncogene D12Rfj1/c-fos 
B08  Mm.135965 NM_177798 Frs2 Fibroblast growth factor receptor substrate 2 4732458E18/C330018A15Rik 
B09  Mm.89912 NM_144939 Frs3 Fibroblast growth factor receptor substrate 3 4930417B13Rik/AI449674 
B10  Mm.277680 NM_139149 Fus Fusion, derived from t(12;16) malignant liposarcoma (human) D430004D17Rik/D930039C12Rik 
B11  Mm.6219 NM_008082 Galr1 Galanin receptor 1 Galnr1 
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B12  Mm.57149 NM_010254 Galr2 Galanin receptor 2 mGalR 
C01  Mm.4679 NM_010275 Gdnf Glial cell line derived neurotrophic factor AI385739 
C02  Mm.88367 NM_010279 Gfra1 Glial cell line derived neurotrophic factor family receptor alpha 1 AU042498 
C03  Mm.32619 NM_008115 Gfra2 Glial cell line derived neurotrophic factor family receptor alpha 2 GFRA2 
C04  Mm.16520 NM_010280 Gfra3 Glial cell line derived neurotrophic factor family receptor alpha 3 Y15110 
C05  Mm.87312 NM_022023 Gmfb Glia maturation factor, beta 3110001H22Rik/3110001O16Rik 
C06  Mm.194536 NM_022024 Gmfg Glia maturation factor, gamma 0610039G16Rik/2310057N07Rik 
C07  Mm.447881 NM_133192 Npffr2 Neuropeptide FF receptor 2 Gpr74/HG31 
C08  Mm.4687 NM_008177 Grpr Gastrin releasing peptide receptor GRP-R 
C09  Mm.10096 NM_010410 Hcrt Hypocretin PPOX 
C10  Mm.246595 NM_198959 Hcrtr1 Hypocretin (orexin) receptor 1 Ox1r 
C11  Mm.335300 NM_198962 Hcrtr2 Hypocretin (orexin) receptor 2 OX2R/mOX2aR 
C12  Mm.465216 NM_013560 Hspb1 Heat shock protein 1 27kDa/Hsp25 
D01  Mm.874 NM_010548 Il10 Interleukin 10 CSIF/Il-10 
D02  Mm.26658 NM_008348 Il10ra Interleukin 10 receptor, alpha AW553859/CDw210 
D03  Mm.222830 NM_008361 Il1b Interleukin 1 beta IL-1beta/Il-1b 
D04  Mm.896 NM_008362 Il1r1 Interleukin 1 receptor, type I CD121a/CD121b 
D05  Mm.1019 NM_031168 Il6 Interleukin 6 Il-6 
D06  Mm.2856 NM_010559 Il6ra Interleukin 6 receptor, alpha CD126/IL-6R 
D07  Mm.4364 NM_010560 Il6st Interleukin 6 signal transducer 5133400A03Rik/AA389424 
D08  Mm.4964 NM_008501 Lif Leukemia inhibitory factor LIF 
D09  Mm.149720 NM_013584 Lifr Leukemia inhibitory factor receptor A230075M04Rik/AW061234 
D10  Mm.27578 NM_019791 Maged1 Melanoma antigen, family D, 1 2810433C11Rik/5430405L04Rik 
D11  Mm.426053 NM_008560 Mc2r Melanocortin 2 receptor ACTHR 
D12  Mm.24001 NM_025282 Mef2c Myocyte enhancer factor 2C 5430401D19Rik/9930028G15Rik 
E01  Mm.2064 NM_013603 Mt3 Metallothionein 3 Mt-3 
E02  Mm.2444 NM_010849 Myc Myelocytomatosis oncogene AU016757/Myc2 
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E03  Mm.255596 NM_010897 Nf1 Neurofibromatosis 1 AW494271/E030030H24Rik 
E04  Mm.1259 NM_013609 Ngf Nerve growth factor Ngfb 
E05  Mm.283893 NM_033217 Ngfr Nerve growth factor receptor (TNFR superfamily, member 16) LNGFR/Tnfrsf16 
E06  Mm.90787 NM_009750 Ngfrap1 Nerve growth factor receptor (TNFRSF16) associated protein 1 AL033356/Bex3 
E07  Mm.425622 NM_008703 Nmbr Neuromedin B receptor BB182387 
E08  Mm.208714 NM_018787 Npff Neuropeptide FF-amide peptide precursor Npff 
E09  Mm.154796 NM_023456 Npy Neuropeptide Y 0710005A05Rik 
E10  Mm.5112 NM_010934 Npy1r Neuropeptide Y receptor Y1 Npyr/Y1-R 
E11  Mm.1433 NM_008731 Npy2r Neuropeptide Y receptor Y2 MGC124241 
E12  Mm.8509 NM_010936 Nr1i2 Nuclear receptor subfamily 1, group I, member 2 PXR/PXR1 
F01  Mm.153432 NM_178591 Nrg1 Neuregulin 1 6030402G23Rik/ARIA 
F02  Mm.443874 NM_032002 Nrg4 Neuregulin 4 AI552600 
F03  Mm.267570 NM_008742 Ntf3 Neurotrophin 3 AI316846/AI835689 
F04  Mm.20344 NM_198190 Ntf5 Neurotrophin 5 2900040K06Rik/AI462899 
F05  Mm.80682 XM_283871 Ntrk1 Neurotrophic tyrosine kinase, receptor, type 1 C80751/Tkr 
F06  Mm.130054 NM_008745 Ntrk2 Neurotrophic tyrosine kinase, receptor, type 2 AI848316/C030027L06Rik 
F07  Mm.301712 NM_018766 Ntsr1 Neurotensin receptor 1 NT-1R/NTR-1 
F08  Mm.57059 NM_008919 Ppyr1 Pancreatic polypeptide receptor 1 NYYR-D/Npy4r 
F09  Mm.86487 NM_008954 Pspn Persephin PSP 
F10  Mm.4630 NM_008964 Ptger2 Prostaglandin E receptor 2 (subtype EP2) EP2/Ptgerep2 
F11  Mm.277406 NM_009283 Stat1 Signal transducer and activator of transcription 1 2010005J02Rik/AA408197 
F12  Mm.293120 NM_019963 Stat2 Signal transducer and activator of transcription 2 1600010G07Rik/AW496480 
G01  Mm.249934 NM_011486 Stat3 Signal transducer and activator of transcription 3 1110034C02Rik/AW109958 
G02  Mm.1550 NM_011487 Stat4 Signal transducer and activator of transcription 4 STAT4 
G03  Mm.425970 NM_019678 Tfg Trk-fused gene AI173908 
G04  Mm.137222 NM_031199 Tgfa Transforming growth factor alpha wa-1/wa1 
G05  Mm.248380 NM_011577 Tgfb1 Transforming growth factor, beta 1 TGF-beta1/TGFbeta1 
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G06  Mm.3248 NM_009365 Tgfb1i1 Transforming growth factor beta 1 induced transcript 1 ARA55/Hic5 
G07  Mm.271833 NM_011611 Cd40 CD40 antigen AI326936/Bp50 
G08  Mm.3597 NM_019548 Tro Trophinin AA409408/Maged3 
G09  Mm.222 NM_011640 Trp53 Transformation related protein 53 bbl/bfy 
G10  Mm.377116 NM_021290 Ucn Urocortin Ucn1 
G11  Mm.292297 NM_022981 Zfp110 Zinc finger protein 110 2900024E01Rik/N28112 
G12  Mm.290924 NM_053009 Zfp91 Zinc finger protein 91 9130014I08Rik/A530054C17Rik 
H01  Mm.3317 NM_010368 Gusb Glucuronidase, beta AI747421/Gur 
H02  Mm.299381 NM_013556 Hprt1 Hypoxanthine guanine phosphoribosyl transferase 1 C81579/HPGRT 
H03  Mm.2180 NM_008302 Hsp90ab1 Heat shock protein 90kDa alpha (cytosolic), class B member 1 90kDa/AL022974 
H04  Mm.343110 NM_008084 Gapdh Glyceraldehyde-3-phosphate dehydrogenase Gapd 
H05  Mm.328431 NM_007393 Actb Actin, beta, cytoplasmic Actx/E430023M04Rik 
H06  N/A SA_00106 MGDC Mouse Genomic DNA Contamination MIGX1B 
H07  N/A SA_00104 RTC Reverse Transcription Control RTC 
H08  N/A SA_00104 RTC Reverse Transcription Control RTC 
H09  N/A SA_00104 RTC Reverse Transcription Control RTC 
H10  N/A SA_00103 PPC Positive PCR Control PPC 
H11  N/A SA_00103 PPC Positive PCR Control PPC 
H12  N/A SA_00103 PPC Positive PCR Control PPC 
 
 
